Pneumothorax After Air Travel in Lymphangioleiomyomatosis, Idiopathic Pulmonary Fibrosis, and Sarcoidosis

Translational Medicine Branch, NationalHeart, Lung, and Blood Institute, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1590, USA.
Chest (Impact Factor: 7.48). 04/2009; 136(3):665-70. DOI: 10.1378/chest.08-3034
Source: PubMed

ABSTRACT The prevalence of pneumothorax associated with travel in patients with interstitial lung diseases is unknown. In patients with lymphangioleiomyomatosis (LAM), in whom pneumothorax is common, patients are often concerned about the occurrence of a life-threatening event during air travel. The aim of this study was to determine the prevalence of pneumothorax associated with air travel in patients with LAM, idiopathic pulmonary fibrosis (IPF), and sarcoidosis.
Records and imaging studies of 449 patients traveling to the National Institutes of Health were reviewed.
A total of 449 patients traveled 1,232 times; 299 by airplane (816 trips) and 150 by land (416 trips). Sixteen of 281 LAM patients arrived at their destination with a pneumothorax. In 5 patients, the diagnosis was made by chest roentgenogram, and in 11 patients by CT scans only. Of the 16 patients, 14 traveled by airplane and 2 by land. Seven of the 16 patients, 1 of whom traveled by train, had a new pneumothorax; 9 patients had chronic pneumothoraces. A new pneumothorax was more likely in patients with large cysts and more severe disease. The frequency of a new pneumothorax for LAM patients who traveled by airplane was 2.9% (1.1 per 100 flights) and by ground transportation, 1.3% (0.5 per 100 trips). No IPF (n = 76) or sarcoidosis (n = 92) patients presented with a pneumothorax.
In interstitial lung diseases with a high prevalence of spontaneous pneumothorax, there is a relatively low risk of pneumothorax following air travel. In LAM, the presence of a pneumothorax associated with air travel may be related to the high incidence of pneumothorax and not to travel itself.

18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A high performance and low power architecture is devised for a 4 Mbps infrared wireless communication system dedicated to the mobile computing. In this architecture, 4PPM(4-Pulse Position Modulation) infrared signals detected by an infrared receiver are digitized into TTL interface level pulses, and the digitized pulses are demodulated by a 1-bit digital demodulator. To improve the dynamic range of the link length, a 4PPM demodulator is synthesized to implement a demodulation algorithm which is constructed so as to accommodate the output tolerance of the infrared receiver. A part of experimental results shows that the realized 4 Mbps infrared communication system can achieve an error free link in the range of 0-140 cm at 90 mW power consumption
    Circuits and Systems, 1996., IEEE Asia Pacific Conference on; 12/1996
  • Chest 10/2009; 136(3):655-6. DOI:10.1378/chest.09-0891 · 7.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphangioleiomyomatosis is a rare pulmonary disease encountered almost exclusively in women of reproductive age. Pulmonary involvement is characterized by multiple thin-walled cysts in the lungs, recurrent pneumothorax, obstructive lung disorders, and progression to chronic respiratory failure over a mean period of 10 years. Certainty of diagnosis requires a lung biopsy, but international criteria have been proposed for a diagnosis without such a biopsy. International recommendations were recently issued for the diagnosis and treatment of lymphangioleiomyomatosis. Treatment is principally symptomatic and relies on the management of bronchial obstruction by bronchodilators; of hypoxemia by oxygen therapy; of pleural complications by pleurodesis, most often surgical; and of renal angiomyolipomas by percutaneous embolization in cases of hemorrhagic risk. Hormone treatment is not recommended. Hopes are high for mTor inhibitors (sirolimus and everolimus) and treatment trials are currently underway. Lung transplantation must be considered when chronic respiratory failure occurs in patients younger than 60 years.
    La Presse Médicale 11/2009; 39(1):116-25. · 1.08 Impact Factor
Show more


18 Reads
Available from